title: A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas.
abstract: OBJECTIVE
  This phase II study evaluated the efficacy and toxicity of weekly cisplatin along with concomitant boost accelerated radiation regimen in patients with locally advanced unresectable head and neck carcinoma.
  
  
  METHODS
  A total of 94 patients (median age, 58 years) with UICC stage III (n = 19) and IV (n = 75) cancer of the oropharynx, larynx, hypopharynx and oral cavity were included. Patients received radiotherapy with a concomitant boost scheme (1.8 Gy on days 1-40 and 1.5 Gy boost on days 25-40 with a total dose of 72 Gy) and concurrent cisplatin, 40 mg/m(2) weekly, for the first 4 weeks.
  
  
  RESULTS
  Most patients (95%) received both radiation and chemotherapy according to protocol. Toxicity was manageable with grade III mucositis and pharyngeal-oesophageal toxicity in 85 and 50% of patients, respectively. Haematological toxicity was mild. Four patients (4%) died due to complications. With a median follow of 41 months, median overall survival and time to progression were 27 and 25 months, respectively. The estimated overall survival at 4 years was 41%.
  
  
  CONCLUSIONS
  Concomitant boost accelerated radiation plus concurrent weekly cisplatin is a feasible schedule in patients with locally advanced unresectable head and neck carcinoma, with acceptable toxicity and survival data.
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Clínico Universitario, Málaga, Spain. jamedina@ya.com
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Medina
authors.forename: Antonio
authors.initials: A
authors.lastname: Rueda
authors.forename: Antonio Sacchetti
authors.initials: AS
authors.lastname: de Pasos
authors.forename: Jorge
authors.initials: J
authors.lastname: Contreras
authors.forename: Manuel
authors.initials: M
authors.lastname: Cobo
authors.forename: Paloma
authors.initials: P
authors.lastname: Moreno
authors.forename: Manuel
authors.initials: M
authors.lastname: Benavides
authors.forename: Asunción
authors.initials: A
authors.lastname: Villanueva
authors.forename: Emilio
authors.initials: E
authors.lastname: Alba
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002945:Cisplatin / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D013030:Spain; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin